StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Research analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.

Other analysts also recently issued reports about the company. Lake Street Capital lowered their price target on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, March 4th.

Ekso Bionics Trading Up 0.2 %

Shares of EKSO opened at $0.45 on Wednesday. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $11.17 million, a P/E ratio of -0.69 and a beta of 1.43. The stock’s fifty day simple moving average is $0.55 and its 200 day simple moving average is $0.77. Ekso Bionics has a twelve month low of $0.34 and a twelve month high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. On average, equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.